Kerasal NeuroCream™ sales off to a good start -

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 25, 2013 at 2:45 AM

Kerasal NeuroCream™ sales off to a good start - Leading drugstore chain Walgreens intends to significantly expands distribution

Walgreens has decided to increase the number of stores selling Kerasal Neurocream™ in U.S. from approximately 1 000 to 7 000 stores. Walgreens is the leading drugstore chain in the U.S. and the increased distribution is an important step towards establishing this innovative product in the marketplace. Kerasal Neurocream™ was launched in September 2013 and sales are off to a good start. Consumer response on advertising has been excellent as well as product feedback from retailers and consumers. The added distribution means that Kerasal Neurocream™ has full distribution at major retailers Walgreens, Walmart, CVS and Rite-Aid, bringing the total store count to more than 21 000. The added distribution is expected to contribute to revenues and earnings in 2014. “I am very pleased with the expanded distribution and the positive reception of Kerasal NeuroCream™ from consumers. Kerasal NeuroCream™ strengthens the Kerasal® brand, our leadership in the topical OTC foot care space in the U.S. and our value to retail partners”, said Steve Cagle, CEO of Moberg Pharma North America. “Kerasal NeuroCream’s™ strong performance in its first few months confirms our strategy. Effective marketing operations in the U.S in combination with our innovation engine continue to deliver value through differentiated products that consumers appreciate”, said Peter Wolpert, CEO of Moberg Pharma AB. About Kerasal NeuroCream™ and foot pain Approximately 30 million Americans experience frequent foot pain[1] (http://#_ftn1) and many simultaneously suffer from cold feet and dry skin. Painful, cold, dry feet may be associated with various conditions, including diabetes, fibromyalgia, shingles, arthritis, joint pain, muscle strain, or trauma. Kerasal NeuroCream™ is a triple action formula that relieves stabbing, burning, tingling foot pain, warms cold feet, and soothes and moisturizes dry skin. Kerasal NeuroCream™ is easily applied with a “no mess” foam applicator. The active ingredients of Kerasal NeuroCream™, capsaicin and camphor, have a well-established use as topical pain relievers, are naturally occurring and derived from plants. Moberg Pharma has utilized its Fusome® skin delivery system, currently used in Moberg’s JointFlex® Pain Relieving Cream, to formulate Kerasal NeuroCream™, enabling a rapid delivery of effective pain relievers to the source of pain. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on November 25, 2013. ---------------------------------------------------------------------- [1] (http://#_ftnref1) The population prevalence of foot and ankle pain in middle and old age: a systematic review. Thomas et al, Pain 2011 Dec For further information, please contact: Peter Wolpert, CEO, Moberg Pharma AB, telephone: +46 707 35 71 35, e-mail: peter.wolpert@mobergpharma.se Peter Östling, IR, Moberg Pharma AB, telephone: +46 76 301 09 78, e-mail: peter.ostling@mobergpharma.se About Moberg Pharma Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 40 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail® and Kaprolac®. Kerasal Nail® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in -licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LBT Unveils Game-Changing Cyclotron for Medical Advances

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Coastal Financial Faces Lawsuit Over Fraud Allegations

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

BETR's Legal Clash: Investor Action Deadline Nears

BETR's Woes in the Legal Spotlight Investors who’ve been keeping an eye on Better Home & Finance Holding Company—trading as BETR on NASDAQ—might wanna pinch themselves. Not every day do you see a class action lawsuit waiting on the horizon like this one. The folks over at Schall, Brown & Schwartz LLP, those wily veterans in shareholder rights litigation, are...

Workday Hits High Note in 2026 Gartner Magic Quadrant

Workday Secures Leadership Position In a wild ride that's left investors with whiplash in recent years, Workday (NASDAQ: WDAY) has firmly planted its flag at the top tier of the 2026 Gartner® Magic Quadrant™ for Cloud ERP Finance. This announcement out of Pleasanton, California, resonates like a victory bell for the company's finance management solutions—a mix of AI,...

Navigating AI Laws: A New Era for Privacy & Security

Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...

D2L Ventures into Vietnam with Van Lang Alliance

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Ryan Stills: Vegan Powerlifter Defies Odds, Wins Sixth World Title

Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...

Endava Faces Securities Fraud Lawsuit: Investor Implications

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...